HIV-associated histoplasmosis early mortality and incidence trends: from neglect to priority

Antoine Adenis1, Mathieu Nacher1, Matthieu Hanf1

  • 1Inserm CIC 1424, Centre d'Investigation Clinique Antilles Guyane, Centre Hospitalier de Cayenne, Cayenne, France; Equipe EA3593, Epidémiologie des Parasitoses et des Mycoses Tropicales, Université des Antilles et de la Guyane, Cayenne, France.

Abstract

Insights

HIV-associated histoplasmosis in French Guiana saw a four-fold decline in early deaths and a three-fold increase in cases. This curable fungal infection is now the leading AIDS-defining illness, with improved diagnosis and treatment contributing to better outcomes.

Area of Science:

  • Tropical medicine
  • Mycology
  • Infectious diseases

Background:

  • Histoplasmosis is endemic in French Guiana, a significant cause of AIDS-defining illness and mortality.
  • Diagnosis of histoplasmosis in French Guiana has improved over two decades.
  • French Guiana serves as a model for Amazonian pathogen ecology.

Purpose of the Study:

  • To describe temporal trends in incidence and mortality for HIV-associated histoplasmosis in French Guiana.

Main Methods:

  • Retrospective study of HIV-associated Histoplasma capsulatum var. capsulatum cases (1992-2011).
  • Analysis of early mortality (death within 30 days of antifungal treatment).
  • Data collected via standardized forms and analyzed using statistical methods.

Main Results:

  • 124 deaths (45.3%) and 46 early deaths (16.8%) occurred among 274 patients.
  • Early mortality proportion declined four-fold (p<0.0001) across three time periods.
  • Annual incident histoplasmosis cases tripled between 1992-1997 and 1998-2004, then stabilized.

Conclusions:

  • AIDS-related histoplasmosis transitioned from rare to the top AIDS-defining event in French Guiana.
  • Early mortality significantly decreased, aligning with North American rates.
  • Increased awareness and capacity building can improve diagnosis and treatment of this curable disease.